I-Mab to Release 1H 2024 Financial Results on August 28, 2024
Get Alerts IMAB Hot Sheet
Join SI Premium – FREE
Conference call to discuss financial results and recent business highlights to take place on
I-Mab Conference Call and Webcast Information:
Investors and analysts are invited to join the conference call at
- Domestic Dial-in: 1-877-407-0784
- International Dial-in: 1-201-689-8560
- Conference ID: 13747695
- Webcast: please click here
Note that Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event.
The Call me™ link will be made active 15 minutes prior to the scheduled start time.
A webcast of the call will also be available on the I-Mab website, on the Upcoming Events section of the Investor Relations page, available by clicking here. A replay of the call will be accessible under the Past Events section of the Investor Relations page and will be archived for 6 months.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.
I-Mab has established operations in
I-Mab Contacts
Investors & Media |
Senior Director, Investor Relations |
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-release-1h-2024-financial-results-on-august-28-2024-302221660.html
SOURCE I-Mab Biopharma
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- SURF'S UP FOR THE WORLD'S PAW-SOME-EST COMPETITORS!
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share